Navigation Links
Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
Date:6/2/2009

EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) announced today the appointment of Klaus Kohl, Ph.D., as Senior Vice President and Chief Technical Officer. Dr. Kohl brings to Bionovo over 20 years of experience in product development and manufacturing. Dr. Kohl will be responsible for manufacturing, quality assurance, and regulatory compliance.

"We are very excited to add Dr. Kohl to our management team," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. He added, "We believe Dr. Kohl's extensive background in the pharmaceutical industry will prove invaluable to Bionovo's current efforts. Klaus' two decades of experience and broad knowledge will optimize our organization to meet with partnering and commercialization standards."

Dr. Kohl's most recent position was as Vice President of Program Management, CMC and Regulatory Affairs at Novo Nordisk Delivery Technologies, where he was responsible for the development of an inhaled insulin drug/device combination product. Prior to Novo Nordisk, Dr. Kohl served as Senior Vice President, Quality and Technical Director at Aradigm Corporation, a specialty pharmaceutical development company focused on respiratory disease management.

From 1985 to 2001, Dr. Kohl worked for Bayer Corporation, where he held various executive positions in quality assurance and drug product development. Before Bayer, Dr. Kohl was engaged in basic research for more than seven years at the Juelich Research Center in Germany, and the Max Planck Institute in Dortmund, Germany.

Dr. Kohl holds an undergraduate degree in Mathematics and Physics from the University of Marburg, Germany, and a master's degree in Experimental Physics and Ph.D. in Biophysics from the University of Aachen, Germany.

Dr. Kohl states, "I feel I am joining
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
2. Bionovo Announces 2008 Highlights and Year-End Financial Results
3. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
4. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
5. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
6. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
7. Bionovo to Present at the Piper Jaffray Healthcare Conference
8. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
9. Bionovo Reports Third Quarter 2008 Financial Results
10. Bionovo to Present at Merriman Curhan Fords Investor Summit 2008 on September 15th
11. Bionovo to Present at Canaccord Adams Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... July 24, 2015  Champions Oncology (OTC-BB: CSBR), a ... and services to personalize the development and use of ... and operational results for the fourth quarter and fiscal ... 28, 2015, before market open. The company ... that day at 9:00 a.m. EDT (6:00 a.m. PDT). ...
(Date:7/24/2015)... -- The global next generation sequencing ... by 2022, growing at an estimated CAGR of 40.1% ... by Grand View Research, Inc. Development of faster, more ... significant reduction in cost of sequencing one base pair. ... of next generation sequencing throughout the forecast period. Revenue ...
(Date:7/23/2015)... LOS ANGELES , July 23, 2015 ImmunoCellular ... plans to report financial results for the second quarter 2015 ... hold a conference call and webcast on that day at ... results and provide a business update. The call will be ...   , , , LIVE CALL: ...
(Date:7/23/2015)... ... July 23, 2015 , ... One hundred years ago ... 1915 National Model Aeroplane Competition, with hopes of winning the Henry S. Villard Trophy. ... centennial. , Participants will have the opportunity to build a Free Flight fantasy club ...
Breaking Biology Technology:Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2
... NEW YORK, August 28 XTL Biopharmaceuticals,Ltd. (NASDAQ: ... biopharmaceutical company,engaged in the acquisition, development and commercialization ... particularly,neuropathic pain and hepatitis C, today announced that ... Company,s depositary bank,The Bank of New York, will ...
... PARIS, August 28 ExonHit Therapeutics, a drug,and ... discovery,collaboration with Allergan Inc. (NYSE: AGN ), ... reached a success milestone.,As a result of the ... human,clinical testing will be initiated on the first ...
... (Nasdaq:,IDMI) today announced that Jeffrey W. Sherman, M.D., F.A.C.P. ... Senior Vice President,of Research and Development. Dr. Sherman will ... and CEO Timothy P. Walbert. Dr. Sherman brings ... and will lead the regulatory and clinical strategy for ...
Cached Biology Technology:Processing Fees on ADRs to be Waived for two Months 2Processing Fees on ADRs to be Waived for two Months 3ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials 2ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 4IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 5
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... The Federation of American Societies for Experimental ... the Science Research Conference (SRC): Glucose transport: Gateway ... Science Research Conference "Glucose transport: Gateway for Metabolic ... role of glucose transport in the control of ...
... of American Societies for Experimental Biology (FASEB) announces ... Conference (SRC): Mitochondrial Assembly and Dynamics in Health, ... Mitochondrial Assembly and Dynamics in Health, Disease and ... where diverse aspects of mitochondrial biology and dysfunction ...
... American Societies for Experimental Biology (FASEB) announces the ... (SRC): Neural Mechanisms in Cardiovascular Regulation. The ... Cardiovascular Regulation, is an important and unique scientific ... regulate normal cardiovascular function, and how dysregulation of ...
Cached Biology News:
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
HOXC11 Antibody...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: